Ionblox Appoints Dr. Shirley Meng to Advisory Board
23.3.2023 18:00:00 EET | Business Wire | Press release
Ionblox, a California-based, advanced lithium-ion battery company, has appointed Dr. Shirley Meng of the University of Chicago to their advisory board. Dr. Meng is a Professor of Molecular Engineering at the University of Chicago as well as the Chief Scientist for Argonne Collaborative Center for Energy Storage Science (ACCESS), and holds a Ph.D. in Advanced Materials for Micro and Nano Systems.
“I look forward to working with the Ionblox team to commercialize their high-performance lithium-ion batteries using a pre-lithiated silicon oxide anode,” said Dr. Meng. “Ionblox is unique in applying a pre-lithiation strategy to their electrode design which is critical for improving the performance and durability of their silicon-based cells.”
At her current positions, Dr. Meng focuses her research on energy storage materials and systems, specifically on rechargeable batteries for electric vehicles, power sources for Internet of Things (IOTs) and sustainable grid-scale storage. Dr. Meng founded the Sustainable Power and Energy Center at the University of California, San Diego, and was the inaugural director at the Institute for Materials Discovery and Design.
“We are thrilled to welcome Dr. Meng to our advisory board and look forward to leveraging her battery insights and expertise,” said Dr. Herman Lopez, CTO and co-founder of Ionblox. “Dr. Meng’s support of Ionblox’s unique pre-lithiated silicon oxide anode technology is a signal to the industry that we’re leading the path toward the next generation of e-mobility applications.”
Silicon anodes suffer from poor cycle life and poor calendar life. After more than a decade of research and development supported by numerous DOE-funded programs (USABC and ARPA-E), Ionblox has demonstrated high-energy, high-power and fast-charging pre-lithiated silicon anode cells with over 1300 DST cycles and 800 days of storage following USABC test protocols. Ionblox’s data in large format pouch cells has been validated by various National Labs and EV and eVTOL OEMs.
In 2022, Ionblox received a new United States Advanced Battery Consortium (USABC) contract to develop low-cost and fast-charge silicon-based cells for EVs. This partnership with USABC will continue to help scale-up the electrification of vehicles across the country and will become especially strong under Dr. Meng’s guidance.
About Ionblox
Founded in Fremont, California in 2017, Ionblox (previously known as Zenlabs) is a next-generation energy company transforming the future of mobility by land and air. The company has more than 40 issued patents, including for the pre-lithiation of all types of silicon-based anodes. Ionblox’s proprietary pre-lithiated silicon oxide anode and cell design enable multiple performance attributes – fast charging, high energy, high power, and long life at low cost – pushing the limits of traditional battery storage technology and unlocking the viability of widespread electric transportation. Ionblox is leading the electric mobility revolution by delivering superior technology and enabling electric vehicle (EV) and electric vertical take-off and landing vehicle (eVTOL) companies to achieve their goals.
Learn more about Ionblox and how it is transforming the future of electric transportation at www.ionblox.com and LinkedIn (@Ionblox).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230323005175/en/
Contact information
Media Contact:
Claire Underwood
Silverline
(540) 494-7552
claire@teamsilverline.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom